Kowloon

Baguio wins EPD service contract worth HK$37 million to provide food waste collection services in New Territories West

Retrieved on: 
Monday, January 16, 2023

Winning this EPD contract highlights Baguio's position as Hong Kong's market leader in food waste collection.

Key Points: 
  • Winning this EPD contract highlights Baguio's position as Hong Kong's market leader in food waste collection.
  • Among the four EPD's recyclable food waste collection service contracts, Baguio has secured half of them (including this contract and Kowloon District contract awarded last year).
  • Under this EPD contract, Baguio will collect approximately 12,000-20,000 tonnes of food waste in total during the contract period.
  • Ms. Ng Yuk Kwan Phyllis, CEO of Baguio, said, "We are pleased to be awarded the New Territories West food waste collection contract after winning a similar contract covering the Kowloon district last year.

Reaching Out to Schools – Privacy Commissioner’s Office Organised the Webinar on “Preventing and Handling of Students’ Misbehaviour involving Cyberbullying and Doxxing”

Retrieved on: 
Monday, January 16, 2023

The webinar was supported by the Education Bureau.

Key Points: 
  • The webinar was supported by the Education Bureau.
  • The Privacy Commissioner for Personal Data (Privacy Commissioner), Ms Ada CHUNG Lai-ling, introduced to the participants the doxxing offences under the Personal Data (Privacy) Amendment Ordinance 2021 and shared some practical tips on how to protect personal data online.
  • Please click here to download Privacy Commissioner's presentation deck (Chinese Only).
  • Please click here to download Mr Li’s presentation deck (Chinese Only).

Hong Kong’s New Bar and Restaurant Additions Shine by the Harbor

Retrieved on: 
Monday, October 31, 2022

Set above the iconic Avenue of Stars on the Kowloon waterfront, sultry DarkSide cocktail bar at Rosewood Hong Kong is home to a serene terrace boasting views of the epic Hong Kong Island skyline.

Key Points: 
  • Set above the iconic Avenue of Stars on the Kowloon waterfront, sultry DarkSide cocktail bar at Rosewood Hong Kong is home to a serene terrace boasting views of the epic Hong Kong Island skyline.
  • In addition to a vast menu of dark spirits like rum, whisky and calvados, the bar serves up contemporary takes on the classics and cocktails inspired by Hong Kong flavors.
  • As golden hour casts a warm glow over the breath-taking Hong Kong Island skyline, theres no better place to soak up the scenery than Hue Dining.
  • Located in the renovated Hong Kong Museum of Art, this modern Aussie restaurant ensures every guest enjoys sweeping views of the glittering harbor thanks to a full wall of panoramic windows.

Hong Kong’s New Bar and Restaurant Additions Shine by the Harbour

Retrieved on: 
Tuesday, October 25, 2022

Set above the iconic Avenue of Stars on the Kowloon waterfront, sultry DarkSide cocktail bar at Rosewood Hong Kong is home to a serene terrace boasting views of the epic Hong Kong Island skyline.

Key Points: 
  • Set above the iconic Avenue of Stars on the Kowloon waterfront, sultry DarkSide cocktail bar at Rosewood Hong Kong is home to a serene terrace boasting views of the epic Hong Kong Island skyline.
  • In addition to a vast menu of dark spirits like rum, whisky and calvados, the bar serves up contemporary takes on the classics and cocktails inspired by Hong Kong flavours.
  • As golden hour casts a warm glow over the breathtaking Hong Kong Island skyline, theres no better place to soak up the scenery than Hue Dining.
  • Located in the renovated Hong Kong Museum of Art, this modern Aussie restaurant ensures every guest enjoys sweeping views of the glittering harbour thanks to a full wall of panoramic windows.

HUTCHMED Highlights Surufatinib and Toripalimab Combination Clinical Data being Presented at the ESMO Immuno-Oncology 2021 Meeting

Retrieved on: 
Friday, December 10, 2021

The approval was based on results from the SANET-ep study, a Phase III trial (clinicaltrials.gov identifier: NCT02588170 ) in patients with advanced epNETs conducted in China.

Key Points: 
  • The approval was based on results from the SANET-ep study, a Phase III trial (clinicaltrials.gov identifier: NCT02588170 ) in patients with advanced epNETs conducted in China.
  • The study met the pre-defined primary endpoint of PFS at a preplanned interim analysis, and was published in The Lancet Oncology1.
  • Pancreatic Neuroendocrine Tumors (pNETs) in China: On June 16, 2021, surufatinib was granted drug registration approval by the NMPA for the treatment of pNET.
  • Earlier, the FDA granted 2 Breakthrough Therapy designations, 1 Fast Track designation, 4 Orphan Drug designations for toripalimab.

Peplink and Telkomsel Join Forces to Bring Unbreakable 4G and 5G SD-WAN in Indonesia

Retrieved on: 
Tuesday, December 7, 2021

Telkomsel is the leading digital telco company in Indonesia that serves more than 169 million customers across Indonesia.

Key Points: 
  • Telkomsel is the leading digital telco company in Indonesia that serves more than 169 million customers across Indonesia.
  • Its IoT services unit, Telkomsel IoT, collaborates with Peplink to power its managed services and solutions.
  • Telkomsel will also have access to Peplinks comprehensive enterprise 5G product portfolio in order to be the first mover with 5G managed SD-WAN.
  • As a way to make it happen, Telkomsel collaborates with the world's leading technology companies such as Peplink.

HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer

Retrieved on: 
Monday, December 6, 2021

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has completed patient enrollment of FRESCO-2, a Phase III registration study of fruquintinib, an investigational treatment for the treatment of patients with metastatic colorectal cancer (“CRC”) in the U.S., Europe, Japan and Australia. The enrollment goal was reached on December 2, 2021.

Key Points: 
  • FRESCO-2 is a randomized, double-blind, placebo-controlled, multicenter trial being conducted in patients with metastatic CRC.
  • This large Phase III trial enrolled patients in over 150 sites in 14 countries.
  • Topline results from the FRESCO-2 trial are expected to be reported in the second half of 2022 when the event-driven primary endpoint, OS, is mature.
  • The U.S. FDA granted Fast Track Designation for the development of fruquintinib for the treatment of patients with metastatic CRC in June2020 .

HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in China

Retrieved on: 
Friday, December 3, 2021

Christian Hogg, Chief Executive Officer of HUTCHMED, said, We welcome the addition of SULANDA into the NRDL, along with the renewal of ELUNATE.

Key Points: 
  • Christian Hogg, Chief Executive Officer of HUTCHMED, said, We welcome the addition of SULANDA into the NRDL, along with the renewal of ELUNATE.
  • It was also included in the 2021 negotiations with the NHSA, however HUTCHMED and AstraZeneca, its partner on ORPATHYS, declined inclusion in the NRDL for 2022.
  • Reimbursement of Category B drugs requires varying degrees of copayment from patients, depending on their province of residence or type of NHSA insurance scheme enrollment.
  • In this latest update of the NRDL, the NHSA is adding or renewing over 30 Category B oncology drugs, including ELUNATE and SULANDA.

Peplink Sees Large Growth in 5G Demand as Partnership with M2M Connectivity Expands 

Retrieved on: 
Thursday, November 25, 2021

MELBOURNE, Australia, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Peplink , a company that makes connectivity reliable, is expanding its partnership with M2M Connectivity, a leading distributor of IoT and wireless innovations in Australia and New Zealand, in response to the growth in market demand for 5G and LTE enterprise connectivity products in the region.

Key Points: 
  • MELBOURNE, Australia, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Peplink , a company that makes connectivity reliable, is expanding its partnership with M2M Connectivity, a leading distributor of IoT and wireless innovations in Australia and New Zealand, in response to the growth in market demand for 5G and LTE enterprise connectivity products in the region.
  • In response, M2M is expanding its Peplink product portfolio to keep up with demand.
  • Adoption of 5G and LTE technologies among businesses is accelerating and the types of industries seeking out these technologies is diversifying.
  • Peplink and M2M had a great start in 2021, we are pleased to see demand for our products increasing in Australia.

HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy

Retrieved on: 
Wednesday, November 24, 2021

HONG KONG and FLORHAM PARK, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/​AIM:​HCM; HKEX:​13) and AstraZeneca PLC (“AstraZeneca”) (LSE/​STO/​Nasdaq:​AZN) have initiated SACHI, a China Phase III study of ORPATHYS® (savolitinib), an oral, potent, and highly selective MET tyrosine kinase inhibitor (“TKI”), in combination with AstraZeneca’s third-generation, irreversible epidermal growth factor receptor (“EGFR”) TKI, TAGRISSO® (osimertinib). The first patient received their first dose on November 22, 2021.

Key Points: 
  • The Phase III trial is a multi-center, open-label, randomized, controlled study in patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) with MET amplification after disease progression on EGFR inhibitor therapy.
  • It is currently under clinical development for multiple tumor types, including lung, kidney, and gastric cancers, as a single treatment and in combination with other medicines.
  • In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing agreement to jointly develop and commercialize savolitinib.
  • Joint development in China is led by HUTCHMED, while AstraZeneca leads development outside of China.